门冬胰岛素30治疗初发2型糖尿病的皮下注射方案比较  

Different injection frequency with biphasic insulin aspart 30 for newly diagnosed type 2 diabetes

作　　者：马波[1] 李红涛[1] 王晓东[1] 包春艳[1] 李春进[1] 吴书元[1] 杨涛[1] 

机构地区：[1]武警天津总队医院内科,天津300162

出　　处：《世界临床药物》2012年第4期221-223,232,共4页World Clinical Drug

摘　　要：目的观察门冬胰岛素30(BIAsp30)一日2次和3次皮下注射方案对初诊2型糖尿病患者的疗效。方法 73例初诊2型糖尿病患者按半随机原则分为A组和B组,A组予BIAsp30一日2次皮下注射,B组予BIAsp30一日3次皮下注射,观察两组患者空腹血糖(FPG)、餐后血糖(PBG)、糖化血红蛋白(HbA1c)及低血糖发生率的差异等。结果与治疗前相比,治疗3个月两组患者血糖水平均显著降低,且治疗后B组早餐后、午餐后、晚餐前及晚餐后血糖水平均低于A组;同时B组PBG水平显著低于A组;B组低血糖发生率也低于A组。结论门冬胰岛素30一日3次治疗初诊2型糖尿病患者疗效显著,安全性高。Objective To observe the efficacy of bid and tid biphasic insulin aspart 30（BIAsp30） in patients with type 2 diabetes. Methods A quasi-randomized controlled trial was performed in 73 newly diagnosed patients with type 2 diabetes. They were divided into group A （BIAsp30, subcutaneous injection, bid） and group B （BIAsp30, sub- cutaneous injection, tid）. The effect of changes in fasting plasma glucose（FPG）, postprandial blood glucose（PBG）, HbAlc and the rate of hypoglycemia were analyzed. Results Afer three months treatment, the glucose level was de- creased significantly in both groups. The levels of blood glucose （after breakfast, after lunch, before dinner and after dinner） in group B were lower than those in group A.The level of PBG and the rate of hypoglycemia in group B were lower than those in group A significantly. Conclusion BIAsp30（subcutaneous injection, tid） is effective and safe in the treatment of newly diagnosed type 2 diabetes patients.

关 键 词：2型糖尿病 门冬胰岛素30 半随机对照研究 治疗应用 

分 类 号：R979.14[医药卫生—药品]